Eramol (UK) Ltd
Eramol | UK Sterile Fill-Finish and Non-Sterile Pharmaceutical Manufacturing CMO
Eramol is an independent UK and EU pharmaceutical contract manufacturing organisation supporting biotechnology, pharmaceutical, academic and investigator-led clinical programmes. Founded, owned and led by Qualified Persons, Eramol provides integrated pharmaceutical manufacturing and clinical-supply services across sterile and non-sterile drug products. Sponsors can access GMP manufacturing, clinical packaging, labelling, QC testing, QP certification, storage and global distribution through one accountable partner.
Sterile fill-finish and injectable manufacturing
Eramol’s purpose-built Sevenoaks facility provides early-phase sterile fill-finish services for injectable drug products, with a focus on Phase I and Phase II clinical-trial supply.
The facility has been designed around EU GMP Annex 1 principles and includes Grade A isolator technology, closed single-use processing, sterile filtration, aseptic processing and moist-heat terminal sterilisation.
Eramol’s aseptic fill-finish capability with <0.1% line losses is engineered to protect scarce and high-value drug substance. This is particularly valuable for early-phase biologics, monoclonal antibodies, antibody-drug conjugates, peptides, oligonucleotides, RNA therapeutics, viral vectors and other complex injectable products where conventional filling losses can materially affect programme cost and available clinical supply.
The flexible small-batch model supports sterile vials, cartridges and pre-filled syringes, with manufacturing designed for programmes requiring technical agility, high filling accuracy and maximum product recovery.
Non-sterile pharmaceutical manufacturing
Eramol’s established Sevenoaks non-sterile pharmaceutical manufacturing facility supports clinical development through to commercial supply.
GMP manufacturing capabilities include:
• Active and placebo tablets
• Coated and uncoated tablets
• Hard-shell capsules
• API neat-fill capsules
• Over-encapsulation and comparator blinding
• Oral solutions and suspensions
• Placebo development and sensory matching
• Clinical and commercial batch manufacture
The facility supports Phase I, Phase II and Phase III programmes, together with commercial manufacturing requirements. Integrated placebo manufacture and blinding capabilities help sponsors maintain study integrity across complex randomised clinical trials.
Integrated clinical manufacturing and supply
Eramol combines sterile and non-sterile manufacturing with clinical packaging services, multilingual labelling, analytical testing, stability support and regulatory oversight.
In-house Qualified Persons provide UK and EU QP release and certification for clinical and commercial products. Through its UK facilities and Dublin EU hub, Eramol can support manufacture, importation, certify and release for supply across the United Kingdom and European Union.
Following QP release, Eramol provides clinical storage and global pharmaceutical distribution, including controlled ambient, refrigerated and frozen storage, validated cold-chain distribution, direct-to-site supply and international clinical logistics.
This integrated model gives sponsors one experienced partner from pharmaceutical manufacturing through to QP release and delivery to clinical sites.
Watch the video here: https://shorturl.at/8VmLC
For more information see: https://eramol.com/ & https://eramol.com/clinical-services-category/sterile-fill-finish/
Eramol is an independent UK and EU pharmaceutical contract manufacturing organisation supporting biotechnology, pharmaceutical, academic and investigator-led clinical programmes. Founded, owned and led by Qualified Persons, Eramol provides integrated pharmaceutical manufacturing and clinical-supply services across sterile and non-sterile drug products. Sponsors can access GMP manufacturing, clinical packaging, labelling, QC testing, QP certification, storage and global distribution through one accountable partner.
Sterile fill-finish and injectable manufacturing
Eramol’s purpose-built Sevenoaks facility provides early-phase sterile fill-finish services for injectable drug products, with a focus on Phase I and Phase II clinical-trial supply.
The facility has been designed around EU GMP Annex 1 principles and includes Grade A isolator technology, closed single-use processing, sterile filtration, aseptic processing and moist-heat terminal sterilisation.
Eramol’s aseptic fill-finish capability with <0.1% line losses is engineered to protect scarce and high-value drug substance. This is particularly valuable for early-phase biologics, monoclonal antibodies, antibody-drug conjugates, peptides, oligonucleotides, RNA therapeutics, viral vectors and other complex injectable products where conventional filling losses can materially affect programme cost and available clinical supply.
The flexible small-batch model supports sterile vials, cartridges and pre-filled syringes, with manufacturing designed for programmes requiring technical agility, high filling accuracy and maximum product recovery.
Non-sterile pharmaceutical manufacturing
Eramol’s established Sevenoaks non-sterile pharmaceutical manufacturing facility supports clinical development through to commercial supply.
GMP manufacturing capabilities include:
• Active and placebo tablets
• Coated and uncoated tablets
• Hard-shell capsules
• API neat-fill capsules
• Over-encapsulation and comparator blinding
• Oral solutions and suspensions
• Placebo development and sensory matching
• Clinical and commercial batch manufacture
The facility supports Phase I, Phase II and Phase III programmes, together with commercial manufacturing requirements. Integrated placebo manufacture and blinding capabilities help sponsors maintain study integrity across complex randomised clinical trials.
Integrated clinical manufacturing and supply
Eramol combines sterile and non-sterile manufacturing with clinical packaging services, multilingual labelling, analytical testing, stability support and regulatory oversight.
In-house Qualified Persons provide UK and EU QP release and certification for clinical and commercial products. Through its UK facilities and Dublin EU hub, Eramol can support manufacture, importation, certify and release for supply across the United Kingdom and European Union.
Following QP release, Eramol provides clinical storage and global pharmaceutical distribution, including controlled ambient, refrigerated and frozen storage, validated cold-chain distribution, direct-to-site supply and international clinical logistics.
This integrated model gives sponsors one experienced partner from pharmaceutical manufacturing through to QP release and delivery to clinical sites.
Watch the video here: https://shorturl.at/8VmLC
For more information see: https://eramol.com/ & https://eramol.com/clinical-services-category/sterile-fill-finish/